spacer
home > ebr > summer 2007 > small but effective: nanoparticles in cancer therapies
PUBLICATIONS
European Biopharmaceutical Review

Small But Effective: Nanoparticles in Cancer Therapies

Ongoing shortcomings in current cancer diagnosis and treatment methods have meant that alternatives are continually being sought for more effective and less toxic treatments, purports Thomas W Rademacher of Midatech

This article investigates the properties of ‘biological’ nanoparticles (nanocells), and how their intrinsic properties can be applied to modern cancer medicine, from their use as imaging agents and drug delivery vehicles to the selected killing of tumour cells by apoptosis, and the prevention of metastasis of cancer cells. Nanocells, with their targeting capacity, size and breadth of properties, provide a new approach to the diagnosis, targeting and treatment of solid tumours.

CANCER:THE UNANSWERED PROBLEM

Cancer is currently the second leading cause of death in both the US and Europe. Global cancer statistics are frightening – 10 million new cases of cancer were reported globally in 2000; however, with an aging population and improved diagnosis, that number is expected to reach 15 million by 2020. Cancer probably shows the highest clinical complexity, with more than 200 known forms of the disease, and often having metastatised by the time a diagnosis is reached.

Although medical research and technological advances have increased our understanding of, and ability to treat many cancers, current therapies – often including a combination of surgery, chemotherapy, immunotherapy and radiotherapy – remain insufficient. Offering more therapeutic options, the advancement of nanotechnology bears the potential to provide an effective answer to the complexity of cancer, and promises tremendous opportunities not only to improve upon existing, well-established treatments, but also to develop new and innovative approaches (1,2).

A number of research groups around the world are designing nanoparticles that have a variety of desirable functions, including the ability to carry molecules (for example drugs, proteins and nucleic acids) into the body, the ability to target these molecules to specific tissues or cells, and physical characteristics that can be used therapeutically. Nanocells combine all of these desirable functions to create a unique and highly versatile technology that promises a range of effective applications in the treatment of cancer.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Thomas W Rademacher is Professor of Molecular Medicine at University College London Medical School. He obtained a Medical Degree in 1976 and a PhD in Biochemistry in 1980, both at the University of Wisconsin- Madison. He was co-founder and Clinical and Research Director of the Glycobiology Institute, University of Oxford, before moving to University College London in 1991. In 1988, Thomas co-founded Oxford GlycoSciences and has since founded several other biotech spin-outs. In 2000, he entered into a collaboration with the Spanish Research Council (CSIC) to form Midatech Ltd.
spacer
Professor Thomas W Rademacher
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing the new Rapidox 7100

When dealing with volatile applications such as those within chemical and combustion processes, you need a high specification instrument you can trust; the Rapidox 7100 Multigas Analyser is that instrument
More info >>

White Papers

Outsourcing and Insourcing: How Eurofins solves the bio/pharma industry’s challenges associated with meeting drug development timelines and budgets with restricted headcounts

Eurofins BioPharma Product Testing

Pharmaceutical and biopharmaceutical companies face a significant challenge to get their drug products developed and launched quickly, all while keeping development costs down. One of the most common ways for companies to lower development costs is to manage fixed headcounts. But when the same scope of work still needs to be completed by a designated time with fewer staff members, this presents a significant challenge. So, how do bio/pharma companies solve this ever so common challenge of increasing output while decreasing headcount? There are essentially three options: temporary staffing, outsourcing, or insourcing.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement